CABALETTA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
CABALETTA BIO, INC. (CABA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.31% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-13
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.91%, a 12.33% decline year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.46%, a 1492.86% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 0.28%, a 92.91% decline year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.95%, a 86.32% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.46%, a 3.04% decline from fiscal 2024.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.60%, a 1.71% decline from fiscal 2023.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.68%, a 11.96% increase from fiscal 2022.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.18%, a 200.72% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.31% 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | 3.91% 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | 4.46% 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | 4.46% 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 4.46% 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | 4.46% 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | 4.60% 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | 4.60% 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 4.60% 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 0.28% 10-Q · filed 2025-05-15 | 4.28% 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | 4.68% 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 4.38% 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 3.95% 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 3.95% 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 4.18% 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | 3.36% 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 3.36% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 2.12% 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 1.39% 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | 1.55% 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | 1.55% 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | 1.01% 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | 1.48% 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | 1.48% 10-Q · filed 2021-11-01 | ||||
| 2020-06-30 | 1.48% 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | 1.48% 10-Q · filed 2021-05-03 | ||||
| 2019-12-31 | 2.59% 10-K · filed 2021-03-16 | ||||
| 2019-09-30 | 2.59% 10-Q · filed 2020-11-10 | ||||
| 2019-06-30 | 2.59% 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | 2.59% 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | 2.96% 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |